The DNA damage induced immune response: Implications for cancer therapy
Related Experiment Video
Updated: Aug 23, 2025

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
Published on: June 9, 2020
Eliana M Barros1, Stuart A McIntosh1, Kienan I Savage1
1Patrick G Johnston Centre for Cancer Research & Cell Biology, Queen's University Belfast, 97 Lisburn Rd, Belfast BT9 7AE, UK.
Abstract:
Genomic instability is a hallmark of tumourigenesis, influencing tumour development and progression. In particular, defects in the DNA damage response (DDR) have been extensively investigated and are known to shape therapeutic response. Since immune checkpoint blockade (ICB) therapy has been approved for treatment of tumours with defective mismatch repair the interplay between DDR pathway deficiency and the immune system has been of particular interest. The cGAS/STING signalling pathway has recently emerged as a key mediator of inflammation in response to DNA damage.This was identified through transcriptional profiling of BRCA1/2 deficient breast cancers and Fanconi Anaemia (FA) patient bone marrow, revealing a common transcriptional subgroup associated with BRCA1/2 and FA deficiency characterised by upregulation of innate immune signalling genes. Additionally, it is now apparent that the DNA damage arising from a multitude of DNA repair defects and DNA damage induced by some classical chemotherapies/radiation also has the ability to induce an innate immune response mediated by cGAS/STING activation. Here we review the role of intrinsic and extrinsic DNA damage in mediating immune activation and its context within tumourigenesis, as well as the potential therapeutic opportunities it represents for the treatment of cancer, such as combining DNA damaging agents with immunotherapies.
Insights
Defects in DNA damage response (DDR) pathways can activate the cGAS/STING innate immune pathway, influencing cancer development and treatment. This interplay offers new therapeutic strategies combining DNA damage agents with immunotherapies.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Genomic instability is a key feature of cancer, impacting tumor progression and treatment outcomes.
- Deficiencies in DNA damage response (DDR) pathways are increasingly recognized for their role in shaping therapeutic responses, particularly with immune checkpoint blockade (ICB) therapy.
- The cGAS/STING signaling pathway is a critical mediator of inflammation in response to DNA damage.
Approach:
- Transcriptional profiling of BRCA1/2 deficient breast cancers and Fanconi Anaemia (FA) patient bone marrow identified a common subgroup with upregulated innate immune signaling.
- The study reviews the literature on intrinsic and extrinsic DNA damage in mediating immune activation.
- The review explores the context of DNA damage-induced immune responses within tumorigenesis.
Key Points:
- DNA damage response defects, such as those in BRCA1/2 and FA, are linked to the activation of innate immune signaling via the cGAS/STING pathway.
- DNA damage, whether from inherent repair defects or external agents like chemotherapy and radiation, can trigger an innate immune response.
- This immune activation presents potential therapeutic opportunities in cancer treatment.
Conclusions:
- The interplay between DNA damage response pathways and the immune system, particularly via cGAS/STING, is crucial in cancer.
- Understanding this connection opens avenues for novel cancer therapies, including the combination of DNA damaging agents with immunotherapies.
Related Concept Videos
Overview of DNA Repair
Chemically...
DNA Damage can Stall the Cell Cycle
Tumor Immunotherapy
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
DNA Damage Can Stall the Cell Cycle

